Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473816 | 0.89 | KMO (0.50) | RAF1P2RX3CYP4F2CYP4A11KDR | |
| SCHEMBL9926361 | 0.84 | RAF1 (0.52) | RAF1P2RX3SCN9ACHEK2BRAF | |
| SCHEMBL619670 | 0.84 | KDR (0.58) | RAF1BRAFOPRK1KDR | |
| SCHEMBL400969 | 0.83 | RAF1 (0.47) | RAF1P2RX3SCN9ABRAFKDR | |
| SCHEMBL4328009 | 0.83 | RAF1 (0.49) | RAF1P2RX3BRAFKDR | |
| SCHEMBL17242259 | 0.82 | SCN9A (0.43) | RAF1P2RX3SCN9ACHEK2 | |
| SCHEMBL177841 | 0.82 | PARP10 (0.54) | RAF1P2RX3CHEK2BRAFOPRK1 | |
| SCHEMBL4359684 | 0.81 | RAF1 (0.46) | RAF1P2RX3BRAFOPRK1KCNH2 | |
| SCHEMBL1137294 | 0.80 | RAF1 (0.58) | RAF1SCN9ABRAFOPRK1KDR | |
| SCHEMBL4369342 | 0.79 | PARP10 (0.54) | RAF1P2RX3CYP4F2CYP4A11BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879676-B1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2879677-B1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-103565653-B | Substituted pyrazolone compound as well as using method and application of pyrazolone compound | 广东东阳光药业有限公司 | 2017-01-25 | — | — | CN | disclosed |
| US-9326975-B2 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-05-03 | — | — | US | disclosed |
| EP-2879676-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2879677-A2 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20150141463-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8975282-B2 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8969388-B1 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-20150050239-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1608639-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | RAF1 1822/4885P2RX3 3215/4885SCN9A 4727/4885 |
| US-20150141463-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | RAF1 10/4885P2RX3 1385/4885SCN9A 4753/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | RAF1 145/4885P2RX3 692/4885SCN9A 1992/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | RAF1 142/4885P2RX3 3287/4885SCN9A 4354/4885 |
| US-20150050239-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | RAF1 10/4885P2RX3 1385/4885SCN9A 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.